PDCD1 and colorectal carcinoma: As of 2025, ICIs such as pembrolizumab (anti-PD-1) and nivolumab, with or without ipilimumab (anti-CTLA-4), are integrated into clinical practice in both neoadjuvant and first-line settings for MSI-H/dMMR CRC.